- Home
- PLX vs MKLY Comparison
PLX vs MKLY Comparison
Compare PLX & MKLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- MKLY
- Stock Information
- Founded
- PLX 1993
- MKLY 2025
- Country
- PLX United States
- MKLY United States
- Employees
- PLX N/A
- MKLY N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- MKLY
- Sector
- PLX Health Care
- MKLY
- Exchange
- PLX Nasdaq
- MKLY Nasdaq
- Market Cap
- PLX 204.9M
- MKLY 237.2M
- IPO Year
- PLX 1998
- MKLY 2025
- Fundamental
- Price
- PLX $2.36
- MKLY $9.95
- Analyst Decision
- PLX Strong Buy
- MKLY
- Analyst Count
- PLX 1
- MKLY 0
- Target Price
- PLX $15.00
- MKLY N/A
- AVG Volume (30 Days)
- PLX 1.1M
- MKLY 125.5K
- Earning Date
- PLX 11-13-2025
- MKLY 01-01-0001
- Dividend Yield
- PLX N/A
- MKLY N/A
- EPS Growth
- PLX N/A
- MKLY N/A
- EPS
- PLX 0.08
- MKLY N/A
- Revenue
- PLX $61,948,000.00
- MKLY N/A
- Revenue This Year
- PLX $14.53
- MKLY N/A
- Revenue Next Year
- PLX $75.77
- MKLY N/A
- P/E Ratio
- PLX $30.48
- MKLY N/A
- Revenue Growth
- PLX 62.79
- MKLY N/A
- 52 Week Low
- PLX $1.02
- MKLY $9.85
- 52 Week High
- PLX $3.10
- MKLY $9.98
- Technical
- Relative Strength Index (RSI)
- PLX 55.84
- MKLY N/A
- Support Level
- PLX $1.60
- MKLY N/A
- Resistance Level
- PLX $2.55
- MKLY N/A
- Average True Range (ATR)
- PLX 0.16
- MKLY 0.00
- MACD
- PLX -0.03
- MKLY 0.00
- Stochastic Oscillator
- PLX 72.51
- MKLY 0.00
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About MKLY McKinley Acquisition Corporation Class A Ordinary Shares
McKinley Acquisition Corp is a blank check company.